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Ablation of the N-type calcium 
channel ameliorates diabetic 
nephropathy with improved 
glycemic control and reduced  
blood pressure
Shoko Ohno1, Hideki Yokoi1, Kiyoshi Mori2, Masato Kasahara3, Koichiro Kuwahara4, 
Junji Fujikura5, Masaki Naito5, Takashige Kuwabara1,6, Hirotaka Imamaki1, Akira Ishii1, 
Moin A. Saleem7, Tomohiro Numata8,9, Yasuo Mori8, Kazuwa Nakao2, Motoko Yanagita1 & 
Masashi Mukoyama1,6
Pharmacological blockade of the N- and L-type calcium channel lessens renal injury in kidney disease 
patients. The significance of specific blockade of α1 subunit of N-type calcium channel, Cav2.2, in 
diabetic nephropathy, however, remains to be clarified. To examine functional roles, we mated 
Cav2.2−/− mice with db/db (diabetic) mice on the C57BLKS background. Cav2.2 was localized in glomeruli 
including podocytes and in distal tubular cells. Diabetic Cav2.2−/− mice significantly reduced urinary 
albumin excretion, glomerular hyperfiltration, blood glucose levels, histological deterioration and 
systolic blood pressure (SBP) with decreased urinary catecholamine compared to diabetic Cav2.2+/+ 
mice. Interestingly, diabetic heterozygous Cav2.2+/− mice also decreased albuminuria, although they 
exhibited comparable systolic blood pressure, sympathetic nerve activity and creatinine clearance 
to diabetic Cav2.2+/+ mice. Consistently, diabetic mice with cilnidipine, an N-/L-type calcium channel 
blocker, showed a reduction in albuminuria and improvement of glomerular changes compared to 
diabetic mice with nitrendipine. In cultured podocytes, depolarization-dependent calcium responses 
were decreased by ω-conotoxin, a Cav2.2-specific inhibitor. Furthermore, reduction of nephrin by 
transforming growth factor-β (TGF-β) in podocytes was abolished with ω-conotoxin, cilnidipine or 
mitogen-activated protein kinase kinase inhibitor. In conclusion, Cav2.2 inhibition exerts renoprotective 
effects against the progression of diabetic nephropathy, partly by protecting podocytes.
Diabetic nephropathy is the most common cause of end-stage renal failure1. To prevent the progression of dia-
betic nephropathy, a strict blood pressure control is strongly recommended1. Although renin-angiotensin system 
(RAS) inhibitors are extensively used as first-choice drugs for diabetic nephropathy2,3, the effects of other antihy-
pertensive drugs on diabetic nephropathy remain elusive4.
Calcium channel blockers (CCBs) are frequently used in combination with RAS inhibitors because of their 
strong blood pressure-lowering properties and minimal adverse side effects4. The voltage-dependent calcium 
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channels are localized in the plasma membrane and are essential for the release of neurotransmitters and hor-
mones5. These channels are classified into L-, P/Q-, N-, R-, and T-type subtypes based on their pharmacological 
and electrophysiological properties. Molecular biological analysis has shown that calcium channels are composed 
of α 1, α 2/δ , β , and γ subunits6, among which α 1 subunits are most important for defining channel properties. The 
α 1 subunit genes have been cloned and classified into the following three subfamilies based on their sequence 
similarity: Cav1.x, Cav2.x, and Cav3.x7. The α 1b subunit Cav2.2, encoded by the CACNA1B gene, is the only sub-
unit which constitutes the N-type calcium channel.
Cilnidipine is an L-/N-type CCB which is used for patients with hypertension8. In several clinical9–11 and 
basic12–14 studies, cilnidipine has been shown to reduce proteinuria compared with other antihypertensive drugs. 
The CARTER study demonstrated that the L-/N-type CCB cilnidipine, but not the L-type CCB amlodipine, 
decreases urinary protein levels in RAS inhibitor-treated hypertensive patients with macroproteinuria11. The 
renoprotective effects of L-/N-type CCBs are at least partly due to the amelioration of glomerular hypertension15. 
L-type CCBs elicit afferent arteriole-prone vasodilation, which may increase the intraglomerular pressure15. On 
the other hand, L-/N-type CCBs ameliorate glomerular hypertension through the vasodilation of both afferent 
and efferent arterioles16.
The N-type calcium channel α 1 subunit knockout (Cav2.2−/−) mice, which lack the cytosolic portion of the 
N-type calcium channel, are viable and have an almost normal behavior but show a very low sympathetic nerve 
activity in atria17. Although previous reports used cilnidipine to inhibit N- and L-type calcium channel in diabetic 
nephropathy, molecular mechanisms of specific N-type calcium channel blockade in glomerular injury are not 
fully investigated. To address these questions, we investigated renal injury in N-type calcium channel-deficient 
db/db mice on the diabetes-prone C57BLKS/J background. In addition, we examined the functional role of 
N-type calcium channel in cultured podocytes.
Results
Characteristics of Diabetic Cav2.2−/− Mice. To examine the role of the N-type calcium channel in dia-
betic nephropathy, we crossed Cav2.2−/− mice with db/m mice on the C57BLKS/J background more than six times 
to obtain db/db Cav2.2−/− mice. All diabetic (db/db) mouse groups showed significantly increased body weights 
compared with those of non-diabetic (db/+ ) controls, and db/db Cav2.2−/− mice tended to have a heavier body 
weight than other db/db mouse groups (Fig. 1a). db/db Cav2.2+/+ mice showed renal hypertrophy, as indicated by 
an increase in kidney weight, whereas db/db Cav2.2−/− mice exhibited less renal hypertrophy (Fig. 1b). We meas-
ured the systolic blood pressure (SBP) of db/+ mice at 8, 12, and 16 weeks of age. db/+ Cav2.2−/− mice showed 
lower SBP than db/+ Cav2.2+/+ mice at 8 weeks of age, and the difference disappeared at 12 and 16 weeks of age 
(Fig. 1c). On the other hand, the SBP of db/db Cav2.2−/− mice remained 15–20 mmHg lower than that of db/
db Cav2.2+/+ mice during the experimental period (Fig. 1d). These results indicate that the deficiency of Cav2.2 
resulted in reduction of basal SBP. To evaluate the mechanism of SBP reduction, we measured urinary catechola-
mine concentrations. db/db Cav2.2−/− mice, but not db/db Cav2.2+/− mice, exhibited 50% lower levels of urinary 
noradrenaline and adrenaline than db/db Cav2.2+/+ mice (Fig. 1e,f).
Improvement of Glucose Metabolism in Cav2.2−/− Mice. To examine glucose metabolism in db/db 
Cav2.2−/− mice, we analyzed 6-h fasting blood glucose levels every 2 weeks during the experimental period. All 
db/db mouse groups showed hyperglycemia at 8 weeks of age, whereas all db/+ mouse groups had normal glu-
cose levels (Fig. 2a). Notably, db/db Cav2.2−/− mice had or tended to have lower levels of blood glucose than db/db 
Cav2.2+/+ mice during the experimental period (Fig. 2a). Sixteen-hour fasting serum insulin levels were not differ-
ent among db/db mouse groups at 16 weeks of age (Fig. 2b). Intraperitoneal glucose tolerance tests (IPGTTs) were 
performed to further evaluate glucose metabolism at 15 weeks of age. The blood glucose levels in GTTs peaked at 
30 min were 250 mg/dL in db/+ Cav2.2−/− mice and 400 mg/dL in db/+ Cav2.2+/+ mice, indicating better glucose 
tolerance in db/+ Cav2.2−/− mice than that in db/+ Cav2.2+/+ mice (Fig. 2c). db/db Cav2.2+/+ mice developed 
severe glucose intolerance, whereas db/db Cav2.2−/− mice exhibited significantly reduced blood glucose levels 
compared with those in db/db Cav2.2+/+ mice (Fig. 2d). The level of HbA1c was also reduced in db/db Cav2.2−/− 
mice compared with db/db Cav2.2+/+ mice (Fig. 2e). Serum insulin levels of db/db mouse groups in GTTs were 
increased compared with those of db/+ mouse groups (Fig. 2f). There was no significant difference among 
db/+ mouse groups. On the other hand, the insulin levels in db/db Cav2.2−/− and db/db Cav2.2+/− mice were 
significantly higher than those of db/db Cav2.2+/+ mice, suggesting that insulin secretion increased in mice with 
Cav2.2 gene deletion.
Insulin tolerance tests (ITTs) were performed to determine whether the improved glucose tolerance observed 
in Cav2.2−/− mice was associated with increased insulin sensitivity. Cav2.2−/− mice showed lower glucose levels 
than Cav2.2+/+ mice in both db/+ and db/db genotypes after insulin injection (Fig. 2g,h). These results indicate 
that deficiency of Cav2.2 improves insulin secretion and insulin sensitivity in diabetic conditions.
Reduced Urinary Albumin Excretion and Improved Hyperfiltration in Diabetic Cav2.2−/− 
Mice. To evaluate the functional alterations in the kidney of diabetic Cav2.2−/− mice, we examined urinary 
albumin excretion and serum creatinine level and calculated creatinine clearance (CCr). At baseline, there 
were no significant differences in urinary albumin excretion between db/+ Cav2.2+/+ and db/+ Cav2.2−/− mice 
(Fig. 3a). Urinary albumin excretion markedly increased in db/db Cav2.2+/+ at 8 weeks of age. In contrast, db/db 
Cav2.2−/− mice exhibited approximately 70% lower urinary albumin excretion than db/db Cav2.2+/+ mice. 
Interestingly, db/db Cav2.2+/− mice also exhibited decreased albuminuria to the level comparable to that of db/db 
Cav2.2−/− mice (Fig. 3a). These results suggest that even a partial ablation of the N-type calcium channel leads to 
reduction in urinary albumin excretion.
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Next, we examined the effect of N-type calcium channel ablation on hyperfiltration induced by diabetic 
milieu by measuring CCr. Basal levels of serum creatinine were not different regardless of the genotype of 
Cav2.2 (Fig. 3b). db/db Cav2.2+/+ mice showed a reduction of serum creatinine levels compared with those in 
db/+ Cav2.2+/+ mice, thus indicating hyperfiltration in diabetic states (Fig. 3b). Although diabetic Cav2.2+/− mice 
Figure 1. Body weight, kidney weights and systolic blood pressure. (a) Time course of body weight changes 
of experimental mice. Body weight in db/db mice significantly increased compared with db/+ mice. (b) Kidney 
weight of experimental mice at 16 weeks of age. db/db Cav2.2−/− mice showed less renal hypertrophy than that 
of db/db Cav2.2+/+ mice. (c,d) Time course of systolic blood pressure changes of db/+ mouse groups (c) and 
db/db mouse groups (d). (e,f) Urinary catecholamine of experimental mice at 16 weeks of age. db/db Cav2.2−/− 
mice showed lower levels of urinary noradrenaline (e) and adrenaline (f) than db/db Cav2.2+/+ mice. db/+ 
Cav2.2+/+ mice (n = 7, white circles), db/+ Cav2.2+/− mice (n = 6, white triangles), db/+ Cav2.2−/− mice (n = 7, 
white squares), db/db Cav2.2+/+ mice (n = 8, black circles), db/db Cav2.2+/− mice (n = 8, black triangles), and db/
db Cav2.2−/− mice (n = 8, black squares). * p < 0.05, * * p < 0.01 vs. Cav2.2+/+ mice of the same db genotype.
www.nature.com/scientificreports/
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Figure 2. Blood glucose, serum insulin, and the results of GTTs and ITTs in db/+ and db/db mice. (a) Time 
course of 6-h fasting blood glucose concentrations. db/db Cav2.2−/− mice had lower levels of blood glucose than  
db/db Cav2.2+/+ mice. (b) Serum insulin levels at 16 weeks of age. There were no different among db/db mice groups.  
(c) IPGTTs (2 g/kgBW) of db/+ mice at 15 weeks of age. db/+ Cav2.2−/− mice showed better glucose tolerance 
compared with db/+ Cav2.2+/+ mice. (d) IPGTTs (1 g/kgBW) of db/db Cav2.2−/− mice at 15weeks of age. db/db 
Cav2.2−/− mice exhibited significantly reduced levels of blood glucose compared with db/db Cav2.2+/+ mice. Since the 
glucometer has a detection limit up to 999 mg/dL, values above the detection limit were treated as 1000 mg/dL. (e) 
Hemoglobin A1c levels at 16 weeks of age. (f) Serum insulin levels of IPGTTs. The insulin levels in db/db Cav2.2−/− 
mice was significantly higher than these of db/db Cav2.2+/+ mice. db/+ Cav2.2+/+ mice (n = 6, white circles), db/+ 
Cav2.2+/− mice (n = 9, white triangles), db/+ Cav2.2−/− mice (n = 7, white squares), db/db Cav2.2+/+ mice (n = 7, 
black circles), db/db Cav2.2+/− mice (n = 7, black triangles), and db/db Cav2.2−/− mice (n = 8, black squares) for 
GTT. (g,h) Blood glucose levels in ITTs at 15 weeks of age of db/+ (g) and db/db (h) mice. db/+ Cav2.2+/+ mice 
(n = 5, white circles), db/+ Cav2.2+/− mice (n = 9, white triangles), db/+ Cav2.2−/− mice (n = 7, white squares), db/db 
Cav2.2+/+ mice (n = 9, black circles), db/db Cav2.2+/− mice (n = 9, black triangles), and db/db Cav2.2−/− mice (n = 7, 
black squares) for ITT. * p < 0.05, * * p < 0.01 compared with Cav2.2+/+ mice of the same db genotype.
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exhibited CCr elevation because of hyperfiltration, the increase in CCr was almost completely abolished in db/db 
Cav2.2−/− mice, suggesting that hyperfiltration was normalized by deletion of the Cav2.2 gene (Fig. 3c).
N-type Calcium Channel Expression in Glomeruli of Control Mice and Renal Histological 
Improvement in Diabetic Cav2.2−/− Mice. N-type calcium channel localization was examined by 
an immunohistochemical study. Cav2.2 was expressed in tubules and glomerular cells in the kidney of both 
db/+ Cav2.2+/+ and db/db Cav2.2+/+ mice (Fig. 3d). Double immunohistochemical staining showed that cells pos-
itive for Cav2.2 in a glomerulus were also positive for WT1, a podocyte marker, indicating that Cav2.2 is expressed 
in podocytes (Fig. 3e).
Figure 3. Role of Cav2.2 on diabetic nephropathy. (a) Time course of urinary albumin excretion per milligram 
creatinine of experimental mice. Urinary albumin excretion of both db/db Cav2.2−/− mice and db/db Cav2.2+/− 
mice was lower than that of db/db Cav2.2+/+ mice. (b) Serum creatinine levels at 16 weeks of age. (c) Creatinine 
clearance at 16 weeks of age. In db/db Cav2.2+/+ mice, creatinine clearance was suppressed to the same level of 
db/+ mice. (d) Immunohistochemical study of Cav2.2 in db/+ Cav2.2+/+ mice and db/db Cav2.2+/+ mice. Cav2.2 
was positive at glomerular cells (arrows). (e) Double immunostaining for Cav2.2 (brown) and WT1 (blue) shows 
double positive cells in a glomerulus (insets). db/+ Cav2.2+/− mice (white triangles), db/+ Cav2.2−/− mice (white 
squares), db/db Cav2.2+/+ mice (black circles), db/db Cav2.2+/− mice (black triangles), and db/db Cav2.2−/− mice 
(black squares). * p < 0.05, * * p < 0.01, vs. db/db Cav2.2+/+ mice. Scale bar = 50 μ m.
www.nature.com/scientificreports/
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We examined renal histology at 16 weeks of age. We observed mesangial expansion with glomerular hypertro-
phy in db/db Cav2.2+/+ mice, which was consistent with diabetic alterations (Fig. 4a). In contrast, db/db Cav2.2−/− 
mice exhibited reduced glomerular mesangial expansion and inhibited glomerular hypertrophy compared with 
those seen in db/db Cav2.2+/+ mice (Fig. 4a). db/db Cav2.2+/− mice also showed ameliorated glomerular changes. 
Figure 4. Histologic examination of a glomerulus. (a) Light microscopic analyses were performed at 16 weeks 
of age, stained with periodic acid-Schiff. db/db Cav2.2−/− mice showed reduced mesangial expansion compared 
with db/db Cav2.2+/+ mice. Scale bar = 50 μ m. (b) Mesangial area in a glomerulus at 16 weeks of age. Mesangial 
area was increased in db/db Cav2.2+/+ mice and was suppressed in db/db Cav2.2−/− mice. (c) Immunostaining 
for nephrin and podocin. db/db Cav2.2−/− mice maintained of nephrin and podocin to the same level with db/+ 
mice. Scale bar = 50 μ m. (d,e) Electron microscopic analyses of glomeruli of experimental mice at 16 weeks 
of age. GBM thickness was ameliorated in db/db Cav2.2−/− mice. Scale bar = 500 nm. * * p < 0.01, vs. db/db 
Cav2.2+/+ mice.
www.nature.com/scientificreports/
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Morphometric analysis revealed that the mesangial area was increased in db/db Cav2.2+/+ mice, whereas this 
increase was significantly suppressed in both db/db Cav2.2−/− and db/db Cav2.2+/− mice (Fig. 4b). These results 
suggest that N-type calcium channel ablation can limit the progression of diabetic nephropathy. Next, we evalu-
ated podocyte injury in these mice. Immunostaining of nephrin and podocin, expressed predominantly in podo-
cytes, was markedly decreased in db/db Cav2.2+/+ mice compared with that in db/+ Cav2.2+/+ mice (Fig. 4c). In 
contrast, db/db Cav2.2−/− mice maintained the expression of nephrin and podocin to the same level as db/+ mice, 
indicating the amelioration of podocyte injury (Fig. 4c). In electron microscopic analysis, db/db Cav2.2+/+ mice 
showed thickening of the glomerular basement membrane (GBM) with slightly widened podocyte foot processes 
(Fig. 4d,e). GBM thickening was significantly ameliorated in db/db Cav2.2−/− mice (Fig. 4e).
Glomerular Gene Expression and Phosphorylation of Extracellular Signal-Regulated Kinase 
(ERK) in Diabetic Cav2.2−/− Mice. Analyses of the glomerular expression of extracellular matrix 
(ECM)-related genes revealed that TGF-β 1 (Tgfb1) mRNA as well as connective tissue growth factor (Ctgf) 
mRNA were increased in db/db Cav2.2+/+ mice, whose increase was significantly reduced in db/db Cav2.2−/− mice 
(Fig. 5a,b). Expression of pro-alpha 3 chain of collagen IV (Col4a3) mRNA was also significantly reduced in 
db/db Cav2.2−/− mice compared with db/db Cav2.2+/+ mice (Fig. 5c). Gene expression of fibronectin (Fn1) and 
pro-alpha 1 chain of collagen I (Col1a1) tended to decrease in db/db Cav2.2−/− mice (Supplementary Fig. S1a,b). 
Glomerular gene expression of Cacna1b, Cav2.2, was not altered in diabetic mice, was reduced in Cav2.2+/− mice 
and was not detected in Cav2.2−/− mice (Fig. 5d). Cav2.2+/− or Cav2.2−/− mice exhibited similar expression of 
Cacna1c, α 1 subunit of L-type calcium channel as Cav2.2+/+ mice (Fig. 5e). Glomerular expression of Cana1g, 
Figure 5. Analysis of glomerular mRNA expression. Real-time RT-PCR analyses of glomerular Tgfb1 (a), 
Ctgf (b) Col4a3 (c) Cacna1b (d) Cacna1c (e) and Cacna1g (f) were shown. Gapdh was used as control. * p < 0.05, 
* * p < 0.01.
www.nature.com/scientificreports/
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α 1 subunit of T-type calcium channel was upregulated in diabetic mice, and was not different among diabetic or 
non-diabetic 3 groups (Fig. 5f).
Activation of extracellular signal-regulated kinase (ERK) has been shown to mediate TGF-β -induced accu-
mulation of ECM protein in diabetic nephropathy18. We found that ERK phosphorylation was increased in glo-
meruli, including mesangial cells and podocytes, of db/db Cav2.2+/+ mice compared with that of db/+ Cav2.2+/+ 
mice (Fig. 6a). Phosphorylation of ERK was significantly lower in the glomeruli of db/db Cav2.2−/− mice than db/
db Cav2.2+/+ mice (Fig. 6a). Macrophages also play a critical role in the progression of diabetic nephropathy19. 
The immunohistochemical study showed that macrophage antigen-2 (Mac2)-positive cells in glomeruli increased 
by 3.0-fold in db/db Cav2.2+/+ mice compared with those in db/+ Cav 2.2+/+ mice (Fig. 6b,c). This increase was 
significantly suppressed in db/db Cav2.2−/− mice (Fig. 6b,c).
Pharmacological Inhibition of L- or N-type Calcium Channel Ameliorates Diabetic 
Nephropathy. To evaluate the pharmacological effect of N-type CCBs, we administered the N-/L-type 
CCB cilnidipine or the L-type CCB nitrendipine to db/db Cav2.2+/+ mice and compared with db/db Cav2.2+/− 
and db/db Cav2.2−/− mice. There was no significant difference in body weight among vehicle-, nitrendipine-, 
cilnidipine-treated, db/db Cav2.2+/− and db/db Cav2.2−/− mouse groups (Supplementary Fig. S2a). Diabetic 
db/db Cav2.2−/− mice exhibited lower blood glucose level than db/db Cav2.2+/− mouse as shown previously 
(Fig. 2a, Supplementary Table S1). Diabetic mice with nitrendipine exhibited high urinary noradrenaline and 
adrenaline excretion, however, diabetic mice with cilnidipine did not change urinary catecholamine levels com-
pared with those with nitrendipine (Supplementary Fig. S2b,c). Administration of nitrendipine or cilnidipine 
showed SBP almost similar to that in the vehicle and db/db Cav2.2+/− mouse groups (Fig. 1d, Supplementary 
Fig. S3a). Diabetic Cav2.2−/− mice showed lower SBP than vehicle, nitrendipine-, cilnidipine-treated and 
db/db Cav2.2+/− mice (Fig. 1d, Supplementary Fig. S3a). Urinary albumin excretion was suppressed in the 
cilnidipine-treated group and not in the nitrendipine-treated group, however, urinary albumin excretion in 
cilnidipine-treated mice was still higher than that in db/db Cav2.2+/− mice (Supplementary Fig. S3b). Renal 
histology showed that treatment with cilnidipine, but not with nitrendipine, inhibited mesangial expansion 
in diabetic mice to the comparable extent of db/db Cav2.2+/− mice (Supplementary Fig. S3c,d). In electron 
Figure 6. Immunohistochemical study for ERK and MAC2. (a) ERK phosphorylation was increased in a 
glomerulus, including mesangial cells and podocytes, of db/db Cav2.2+/+ mice. Its increase was ameliorated 
in a glomerulus of db/db Cav2.2−/− mice. (b,c) Mac-2-positive cells in glomeruli increased in db/db Cav2.2+/+ 
mice compared with those in db/+ Cav 2.2+/+ mice and suppressed in db/db Cav2.2−/− mice. * * p < 0.01. Scale 
bar = 50 μm.
www.nature.com/scientificreports/
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microscopic analysis, footprocesses widening and GBM thickening in diabetic mice was ameliorated only by 
cilnidipine treatment, which was comparable to db/db Cav2.2−/− mice (Supplementary Fig. S3e,f). Glomerular 
expression of TGF-β 1 (Tgfb1) and connective tissue growth factor (Ctgf) mRNA tended to show a reduction 
in cilnidipine-treated mice, but the difference was not significant (Supplementary Fig. S4a,b). Accumulation of 
macrophages was decreased in cilnidipine-treated mice compared with vehicle-treated mice (Supplementary Fig. 
S4c,d).
The Functional Role of N-type Calcium Channel on Cultured Podocytes. First of all, to examine the 
role of the N-type calcium channel on podocytes, we measured intracellular Ca2+ ([Ca2+]i) concentration in cul-
tured human podocytes. When podocytes were stimulated with 107 mM KCl, depolarization-dependent [Ca2+]i 
increase was observed, and this [Ca2+]i concentration was partially abolished by treatment with the N-type 
calcium channel blocker, ω -conotoxin (Fig. 7a,b). We also found that nifedipine, cilnidipine, or ω -conotoxin 
plus nifedipine inhibited depolarization-induced [Ca2+]i in cultured podocytes (Fig. 7c,d). These results suggest 
that both N-type and L-type calcium channels are expressed in cultured human podocytes and are relevant to 
depolarization-induced [Ca2+]i increase.
To confirm the effect of N-type calcium channel blockade on podocytes, we examined the changes in nephrin 
expression in cultured human podocytes treated with ω -conotoxin. Administration of exogenous TGF-β 
resulted in a decreased expression of nephrin in podocytes (Fig. 7e). This decrease was significantly reversed by 
pre-incubation with ω -conotoxin (Fig. 7e). Nitrendipine did not change the TGF-β -induced reduction of nephrin 
expression, but cilnidipine upregulated nephrin expression in podocytes (Fig. 7f).
Finally, we revealed that inhibition of ERK by mitogen-activated kinase kinase (MEK) inhibitor U0126 signif-
icantly ameliorated TGF-β -induce reduction of nephrin expression (Fig. 7g).
Discussion
Investigation of diabetic nephropathy in rodents is rendered difficult partly by the lack of adequate animal models 
displaying typical diabetic nephropathy20. Among these limited mouse models of diabetic nephropathy, db/db 
mice are one of the most frequently used disease models. Nevertheless, the genetic background plays an impor-
tant role in developing diabetic nephropathy; e.g., db/db mice on the C57BLKS background exhibit massive 
proteinuria and mesangial expansion, whereas db/db mice on the C57BL/6J show less severe glomerular and 
glycemic changes20,21. Knockout mice are mostly generated on the C57BL/6J or 129/SvJ backgrounds22. In order 
to overcome these situations, we backcrossed Cav2.2 knockout mice on the C57BL/6J background with C57BLKS 
to explore the role of the N-type calcium channel in diabetic nephropathy.
The present study demonstrated that glycemic control was improved with enhanced insulin secretion in dia-
betic mice by ablation of the N-type calcium channel. In a previous study, Cav2.2−/− mice showed lower fasting 
glucose levels and better glucose tolerance than wild-type mice without any change in insulin sensitivity upon 
GTTs23. The same study reported that, after 10 weeks of high-fat diet feeding, Cav2.2−/− mice still showed lower 
fasting glucose levels and better glucose tolerance than Cav2.2+/+ and Cav2.2+/− mice. The mechanisms how 
Cav2.2 deletion resulted in better glycemic control have not been clarified yet, but another report has shown that 
the N-type calcium channel is present on pancreatic α cells and that GLP-1 inhibits glucagon release by selectively 
suppressing this channel24. In our study, db/db Cav2.2+/− mice showed a marginally improved glucose tolerance; 
however, the reduction in urinary albumin excretion was much larger than expected from the degree of glycemic 
control, suggesting that mechanisms other than the amelioration in glucose metabolism would contribute to 
renoprotective effects, particularly in db/db Cav2.2+/− mice.
Diabetic Cav2.2−/− mice showed lower SBP with a marked reduction in urinary catecholamine levels. Similarly, 
a previous report showed that Cav2.2−/− mice exhibited lower SBP than control mice because of vasodilatation, 
reduction of heart contractile activity, and inhibition of sympathetic nerve activity25. Most notably in our study, 
urinary albumin excretion was reduced by 70% and renal hyperfiltration was normalized in db/db Cav2.2−/− mice. 
In addition, even diabetic Cav2.2+/− mice, in which the expression of the N-type calcium channel is ~50% less 
than wild-type mice, showed a decrease in albuminuria to the level comparable to that in diabetic Cav2.2−/− mice. 
The former denied reduction in sympathetic nerve activity, suggesting that partial inhibition of the N-type cal-
cium channel could ameliorate albuminuria without affecting sympathetic nerve function.
Cilnidipine has been shown to ameliorate glomerular hypertrophy by dilating both afferent and efferent arte-
rioles in the kidney12,16, and L-type calcium channel blockade does not improve glomerular hypertension because 
the L-type calcium channel blockade mainly dilates afferent arterioles15. Because N-type calcium channels exist 
at synaptic nerve endings26 in both the afferent and efferent arterioles, and the blockade of the N-type calcium 
channel inhibits norepinephrine release26, such sympatholytic effect of the N-type calcium channel ablation may 
have worked to ameliorate glomerular injury in our study. Cilnidipine showed similar antihypertensive effects 
and suppression of proteinuria both in innervated and denervated spontaneous hypertensive rat (SHR)27, thus 
suggesting that renal sympathetic nerves may have a limited contribution to its renoprotective effects. In our 
study, albuminuria as well as glomerular histological changes were significantly alleviated in db/db Cav2.2+/− mice 
and cilnidipine-treated diabetic mice without reduction of urinary catecholamine levels, further providing a pos-
sibility for mechanisms independent of the sympathetic nerve activity. In addition, we showed no compensatory 
expression of α 1 subunits of L- and T- type calcium channel in Cav2.2 heterozygous or knockout mice. Further 
study is necessary to distinguish the effects of N- and T- type calcium channel blocker, because blockade of 
T-/L-type calcium channel by manidipine28 or efonidipine29 exhibit similar effects as N-/L-type calcium channel 
blocker, cilnidipine, in terms of amelioration of glomerular hypertension.
As diabetic N-type calcium channel knockout mice improved metabolic parameters including glycemic con-
trol and blood pressure, the amelioration of diabetic renal injury in N-type calcium channel knockout mice 
is partly due to simultaneous improvements of metabolic parameters. However, in addition to these actions, 
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Figure 7. Expression of N-type calcium channels in cultured human podocytes and the functional role of 
these channels in depolarization-induced Ca2+ response. (a,b) Inhibitory effect of 3 μ M ω -conotoxin (black 
squares) on depolarization-induced Ca2+ responses in human podocyte (n = 27–39) compared with control 
(white squares). (a) Averaged time courses of depolarization-induced Ca2+ response in human podocyte.  
(b) The bars represent the differences between the maximum of ration and the value of steady state. * p < 0.05 
vs. control. (c,d) Inhibitory effect of 3 μ M cilnidipine and 3 μ M nifedipine on depolarization-induced Ca2+ 
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we showed possible functional roles of the N-type calcium channel in podocytes. Previous reports showed that 
glomerular podocytes express the N-type calcium channel13,27. Fan et al. demonstrated the immunoreactivity of 
N-type calcium channels in kidney vascular walls, possibly in the nerves in adventitia, distal tubules, and podo-
cytes, and that the N-type calcium channel in cultured podocytes was involved in the angiotensin II-induced 
production of reactive oxygen species13. In the present study, we also found that the N-type calcium channel is 
expressed in glomeruli, presumably podocytes, in control mice. The genetic inhibition of N-type calcium channels 
reduced podocyte injury in diabetic mice. In vitro analysis using calcium imaging revealed that N-type calcium 
channels as well as L-type calcium channels are functional in depolarization-induced [Ca2+]i increase in cultured 
human podocytes. Furthermore, we examined the changes in nephrin expression induced by TGF-β stimulation 
in cultured human podocytes and revealed that the decrease caused by the administration of exogenous TGF-β 
was canceled by pre-incubation with ω -conotoxin, cilnidipine or MEK inhibitor. High glucose-induced ERK 
activation in podocytes is closely associated with diabetic nephropathy through the protein kinase C pathway30,31, 
suggesting that ERK plays an important role in TGF-β -induced podocyte injury.
In conclusion, we have demonstrated that the ablation or blockade of the N-type calcium channel in diabetic 
mice exerts renoprotective effects, which effects may be brought about by both improvement of metabolic param-
eters and protection from podocyte injury. These results indicate that the N-type calcium channel works as an 
aggravating factor in a mouse model of diabetic nephropathy, suggesting a possibility that the N-type calcium 
channel should provide a promising therapeutic target for preventing the progression of diabetic nephropathy in 
humans.
Methods
Animals and drug treatment. All animal experiments were approved by the Animal Experimentation 
Committee of Kyoto University Graduate School of Medicine and were carried out in accordance with the 
approved guidelines. Mice deficient in the α 1B subunit of the N-type calcium channel (Cav2.2−/− mice) were 
produced on the 129/SvJ background17 and then backcrossed with C57BL/6J mice more than 10 times. BKS.
Dg-Dock7m + /+ Leprdb/J mice (db/m) mice on the C57BLKS/J background were purchased from Clea Japan Co. 
Ltd (Tokyo, Japan). Cav2.2−/− mice were backcrossed with db/m mice on C57BLKS/J more than six times. We 
prepared six groups as follows: db/+ Cav2.2+/+ mice, db/+ Cav2.2+/− mice, db/+ Cav2.2−/− mice, db/db Cav2.2+/+ 
mice, db/db Cav2.2+/− mice, and db/db Cav2.2−/− mice. Male diabetic db/db mice and their non-diabetic db/+ 
mice (control) were used in this study. Blood pressure was measured by the tail-cuff method (MK-2000ST; 
Muromachi Kikai, Tokyo, Japan) every 4 weeks32. Urine samples were collected using metabolic cages every 2 
weeks for measurement of creatinine and albumin28. Thereafter, mice were sacrificed at 16 weeks of age.
Nitrendipine (15 mg/kg/day; a gift from Tanabe Mitsubishi pharmaceutical company), cilnidipine (15 mg/kg/
day; a gift from Mochida pharmaceutical company) or vehicle were mixed with powdered food at 150–187.5 μ g/g, 
the concentration of which is adjusted by weekly food intake. CCBs were administered to db/db Cav2.2+/+ mice 
from 9 weeks to 16 weeks of age.
Blood and urine parameter measurements. Serum and urinary creatinine levels were assayed by an 
enzymatic method (SRL, Tokyo, Japan)32. Blood glucose was measured with Gunze Life Check (Gunze, Tokyo, 
Japan)33. Plasma insulin levels were measured by enzyme immunoassay (Ultra-sensitive PLUS mouse insulin 
kit, Morinaga, Yokohama, Japan)34. For GTTs, after 16-h fasting, db/+ mice and db/db mice received ip injec-
tions with 2 or 1 g/kg glucose, respectively34. For insulin tolerance tests (ITTs), after 16-h fasting, db/+ mice and 
db/db mice received ip injections with 0.4 and 2 units/kg human insulin (Novo Nordisk, Bagsvaerd, Denmark), 
respectively34. We measured catecholamines in 24-h urine by adding 1 mL 6N HCl per 100 ml of urine. Urinary 
catecholamine contents were measured by high-performance liquid chromatography (SRL, Tokyo, Japan). 
Urinary albumin was measured with murine albumin enzyme-linked immunosorbent assay (ELISA) kit (Exocell, 
Philadelphia, PA)32. HbA1c values were determined as described previously33.
Renal histology, immunohistochemistry, and electron microscopy. Histologic and immunohis-
tochemical examinations were performed as described previously32. Immunofluorescence analyses for nephrin 
and podocin were performed as described previously32. Immunohistochemical studies for phospho-ERK and 
Mac2 (also known as lectin galactoside-binding soluble 3, LGALS3) were performed as described19,32. For the 
double immunohistochemical study for Wilms’ tumor factor-1 (WT1) and Cav2.2, kidney sections were fixed 
with Brasil’s fixative. Sections were boiled for 10 min for antigen retrieval. After blocking, sections were incubated 
with both goat anti-WT-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-Cav2.2 anti-
body (Alomone Labs, Jerusalem, Israel) for 1 h at room temperature. Then, sections were incubated with alkaline 
phosphatase-conjugated anti-goat IgG and peroxidase-conjugated anti-rabbit IgG (Jackson ImmunoResearch, 
responses in human podocyte (n = 20–30). (c) Averaged time courses of depolarization-induced Ca2+ response 
in human podocyte. 3 μ M nifedipine; black squares, 3 μ M cilnidipine; black circles, 3 μ M ω -conotoxin + 3 μ M 
nifedipine; white circles, DMSO; white squares. (d) The bars represent the differences between the maximum 
of ratio and the value of steady state. * p < 0.05, * * p < 0.01, * * * p < 0.001 vs. DMSO. (e) TGF-β 1 (20 ng/
ml) suppressed NPHS1 expression in cultured human podocytes. Its inhibition was canceled by 100 nM ω 
-conotoxin. n = 11 for TGF-β (− ) groups and n = 12 for TGF-β (+ ) groups. (f) Cilnidipine (10 μ M) not 
nitrendipine (10 μ M) ameliorated reduction of NPHS1 expression induced by 5 ng/ml TGF-β 1 in podocytes. 
Vehicle (n = 5) and other groups (n = 6, each). * p < 0.05, * * p < 0.01. GAPDH was used as control.
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West Grove, PA) for 1 h. Electron microscopy analysis was performed as described previously32. The GBM thick-
ness was measured with the Image J software (Ver 1.45; National Institutes of Health, Bethesda, MD).
Real-time RT-PCR analysis. Total RNA was extracted using AllPrep DNA/RNA/Protein Mini Kit 
(Qiagen, Germantown, MD) from glomeruli that were isolated by the graded sieving method32. Quantitative 
real-time PCR was performed using Premix Ex Taq (Takara Bio, Otsu, Japan) on the StepOnePlus system 
(Applied Biosystems, Foster City, CA) as described previously35. Glomerular expression of Tgfb1, Ctgf, Col4a3, 
Cacna1b, Cacna1c, Cacna1g, Fn1 and Col1a1 mRNA was evaluated. Some of primers and probe sets were 
described elsewhere32 and as follows: Cacna1b forward primer, 5′ -gagactccaggggctgacac-3′ ; Cacna1b reverse 
primer, 5′ -cgttcagtggcctcctccg-3′ ; Cacna1b probe, 5′ -FAM-cagtagacgtcaccaccggcgcg-TAMRA-3′ ; Cacna1c for-
ward primer, 5′ -agactgagtctgtcaacactga-3′ ; Cacna1c reverse primer, 5′ -ggagatccgatgggcaagc-3′ ; Cacna1c probe, 
5′ -FAM-ttctccctcgatgtcacctccagcca-TAMRA-3′ ; Cacna1g forward primer, 5′ -ccgagagatccctaggacaca-3′ ; Cacna1g 
reverse primer, 5′ -gtgtctgctggttgggagtg-3′ ; Cacna1g probe, 5′ -FAM-cccaaagcccagtcaggctccatctt-TAMRA-3′ . 
Expression of each mRNA was normalized with GAPDH mRNA (TaqMan rodent GAPDH control reagents; 
Applied Biosystems).
Cell culture. Conditionally immortalized human podocytes were cultured as described previously36,37. 
Differentiated podocytes were serum-starved for 24 h and then pretreated with 100 nM ω -conotoxin (Peptide 
Institute, Osaka, Japan)38, 10 μ M cilnidipine or 10 μ M nitrendipine at 1 h before the stimulation of recombinant 
human TGF-β 1 (R&D Systems, Minneapolis, MN). Cells were harvested after 24 h, and the expression level of 
nephrin was assayed by real-time RT-PCR analysis (n = 5–12).
Calcium imaging. Calcium imaging was performed as described previously with some modification39. 
Human podocyte cells were plated onto poly-L-lysine-coated glass coverslips and subjected to measurement 
3–16 h after plating on the coverslips. The cells on coverslips were loaded with fura-2 in RPMI 1640 containing 
1 μ M fura-2-acetoxymethyl ester (fura-2-AM; Dojindo Laboratories, Kumamoto, Japan), 10% fetal bovine serum 
(Sigma), 10 μ g/mL insulin, 5.5 μ g/mL transferrin, 5 ng/mL selenium (Sigma), 30 units/mL penicillin, and 30 μg/
mL streptomycin at 37 °C for 30 min. The coverslips were then plated in a perfusion chamber mounted on the 
stage of the microscope. The fura-2 fluorescence images of the cells were recorded in HEPES-buffered saline 
(HBS, 2 mM Ca2+) (in mM): 107 NaCl, 6 KCl, 1.2 MgSO4, 2 CaCl2, 1.2 KH2PO4, 11.5 glucose, and 20 HEPES (pH 
7.4 adjusted with NaOH). Four minutes after image acquisition, the cells were stimulated with 107 mM K+ solu-
tion (in mM): 107 KCl, 6 NaCl, 1.2 MgSO4, 2 CaCl2, 1.2 KH2PO4, 11.5 glucose, and 20 HEPES (pH 7.4 adjusted 
with NaOH). All the reagents dissolved in water or dimethylsulfoxide were diluted to their final concentrations 
and applied to the cells by perfusion. Fluorescence images of the cells were recorded and analyzed with a video 
image analysis system (AQUACOSMOS; Hamamatsu Photonics, Shizuoka, Japan). The ratio of the fluorescence 
intensity at 340 nm to the intensity at 380 nm was calculated to evaluate the change in intracellular calcium levels.
Statistical analysis. Data are expressed as the mean ± SEM. Statistical analysis was performed using 
one-way ANOVA. P < 0.05 was considered statistically significant.
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